A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX).

Trial Profile

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Cangrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Myocardial infarction; Stent thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CHAMPION; CHAMPION-PHOENIX; PHOENIX
  • Sponsors The Medicines Company
  • Most Recent Events

    • 18 Jul 2017 Results of a prespecified subgroup analysis assessing efficacy and safety of cangrelor in the subgroup of patients who received unfractionated heparin (UFH) during PCI (n=7569) published in the American Journal of Cardiology
    • 10 Jun 2017 Biomarkers information updated
    • 06 Apr 2017 Results of ccurrence of dyspnoea and associated clinical outcomes published in the Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top